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A B S T R A C TObjectives: Health technology assessments (HTAs) typically require the
development of a cost-effectiveness model, which necessitates the
identiﬁcation, selection, and use of other types of information beyond
clinical effectiveness evidence to populate the model parameters.
The reviewing activity associated with model development should be
transparent and reproducible but can result in a tension between being
both timely and systematic. Little procedural guidance exists in this
area. The purpose of this article was to provide guidance, informed by
focus groups, on what might constitute a systematic and transparent
approach to reviewing information to populate model parameters.
Methods: A focus group series was held with HTA experts in the United
Kingdom including systematic reviewers, information specialists, and
health economic modelers to explore these issues. Framework analysis
was used to analyze the qualitative data elicited during focus groups.
Results: Suggestions included the use of rapid reviewing methods and
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4DA, UK.need for transparency in the reporting of review methods was empha-
sized. It was suggested that additional attention should be given to the
reporting of parameters deemed to be more important to the model or
where the preferred decision regarding the choice of evidence is
equivocal. Discussion: These recommendations form part of a Techni-
cal Support Document produced for the National Institute for Health
and Clinical Excellence Decision Support Unit in the United Kingdom.
It is intended that these recommendations will help to ensure a more
systematic, transparent, and reproducible process for the review of
model parameters within HTA.
Keywords: cost-effectiveness modeling, evidence-based decision
making, health technology assessment, model parameters,
systematic review methods.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Health technology assessment (HTA) reports used to inform
evidence-based decisions concerning the use of health care inter-
ventions typically involve the development of a systematic review of
clinical effectiveness and the development of a cost-effectiveness
model. By its very nature, the development of the model requires
information beyond clinical efﬁcacy such as health utilities, resource
use, and costs. In addition, the model structure requires the use of
evidence to inform judgments concerning the plausibility of relation-
ships between intermediate and ﬁnal end points, as well as other
information to determine what is relevant for inclusion in themodel.
The way in which this evidence is used can have a fundamental
impact on results of the model and ultimately the decision outcome
[1]. The main groups of information needs are illustrated in Figure 1.
It should be noted that the ﬁve categories presented are notmutually
exclusive and there will be overlap between them. The information
needs represented here include both soft contextual information and
harder experimental or nonexperimental evidence.
A number of issues need to be considered when reviewing
evidence to inform the speciﬁcation and population of cost-effectiveness models. These include the timelines for HTA, which
may be restrictive, because decisions on technologies are often
needed as near to the time of licensing as possible and often before
clinical effectiveness has been established. There is also a need for
methods that are systematic, transparent, and reproducible to
minimize the risk of bias and therefore produce more robust
results. If model results are to be considered credible, researchers
need to be transparent about how the model was developed and
why certain inputs should be considered reliable. Sources of
evidence may vary widely between models. These sources include
randomized controlled trials, observational evidence and other
clinical studies, registry databases, elicitation of expert clinical
judgment, existing cost-effectiveness models, routine data sources,
and health valuation studies. Previous work by Coyle et al. [2]
looked at the most common data elements within models (clinical
effect sizes, baseline clinical data, resource use, unit costs, and
utilities) and developed a hierarchy of data sources for these. For
clinical effect size, the authors recommend the highest level of
evidence to be meta-analysis of randomized controlled trials with
direct comparison between comparator therapies and the lowest
ranking evidence to be expert opinion. For another evidenceociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Related Research, University of Shefﬁeld, Regent Court, 30 Regent
Fig. 1 – Types of evidence used to inform models.
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collection or analysis of reliable administrative data to be the
highest level of evidence, with expert opinion again the lowest.
While reviewing processes are often used to identify evidence
for economic models, it is less usual for model reports to describe
and justify how they have identiﬁed and synthesized the evidence
beyond the efﬁcacy data or for reports to set out criteria against
which the relevance and quality of the evidence are assessed [3].
While some of the issues surrounding reviewing evidence for
models have been discussed previously [1,3–8], there remains very
little formal guidance with respect to best practice in this area.
Briggs et al. [9] in their ISPOR-SMDM Modeling Good Research
Practice report recommend that analysts should conform to the
broad principles of evidence‐based medicine and avoid “cherry
picking” the best single source of evidence. Thus, the selection of
sources of evidence for model parameters should follow a system-
atic and transparent approach. Coyle and Lee [1] demonstrated
that using different sources of evidence can have a substantial
impact on the results and highlighted that there is a lack of
agreement as to what constitutes good evidence for speciﬁc data
inputs in economic models. It has further been argued that one
potential source of errors in HTA models is the separation of
information gathering, reviewing, and modeling functions [10].
Current methodological guidance regarding the reviewing of
evidence to inform model parameters, apart from clinical effec-
tiveness from the National Institute for Health and Clinical
Excellence (NICE), states: “For all parameters (including effective-
ness, valuation of HRQL and costs) a systematic consideration of
possible data sources is required” [11]. This absence of clarity
presents a considerable challenge to organizations submitting
evidence to NICE because a full systematic review is clearly not
required for each parameter, yet it is not clear what a “systematic
consideration” is. A recent Technical Support Document (TSD)
from the NICE Decision Support Unit [12] considers the require-
ments and provides methodological guidance for identifying and
reviewing evidence to inform models of cost-effectiveness, in
particular model parameter estimates, in the NICE Technology
Appraisal Process. While this was developed to inform assess-
ments of pharmaceutical interventions, it also has a wider
relevance to the appraisal of medical devices and diagnostic
techniques. Issues surrounding the identiﬁcation, review, and
selection of evidence to inform model parameter values are
relevant to economic analyses that involve secondary data alone
as well as those in which a combination of primary and
secondary data is required. When economic analyses areundertaken alongside a clinical trial, it is rare that full evidence
requirements to assess costs and effect of the technology would
be sourced from the trial alone [13]. Part of the TSD provides
guidance on methods for reviewing model parameter data in a
systematic fashion. It draws distinctions between systematic
reviews and reviewing in the context of informing model param-
eters and demonstrates how the key components of systematic
review methods can be used to systematize and make explicit
the choices involved in selecting evidence to inform models.
Individual model parameters will have different characteristics
and therefore varying evidence requirements, information avail-
ability, and reviewing needs. The purpose of this article was to
provide guidance, informed by a series of focus groups, on what
might constitute a systematic and transparent approach to
reviewing information to populate model parameters where
there is no requirement to use conventional systematic review
methods and where little procedural guidance exists. While
precise methods that should be used to review individual
evidence types should be judged on a case-by-case basis, issues
that need to be considered should not. This article highlights
what these considerations are and emphasizes the importance of
being transparent in how such judgments are reached. The
article describes the methods used and identiﬁes seven key
themes related to the reviewing of evidence for model parame-
ters and provides further analysis of key themes in the
discussion.Methods
A series of focus groups was used to gather information on issues
around reviewing for model parameters and provide the basis of
recommendations covered in the TSD. An initial pilot focus group
was held with 18 researchers who had extensive experience in
HTA including 6 systematic reviewers, 2 information specialists,
and 10 health economic modelers in January 2010. The research-
ers were all from the School of Health and Related Research at
the University of Shefﬁeld, which is a major provider of HTA
reports in the United Kingdom. A range of people with different
areas and of expertise in HTA was invited to attend the focus
group; these individuals were identiﬁed purposively to reﬂect the
breadth of input into the model development process. A topic
guide was developed to structure the discussion within the focus
group and was informed through discussion with experts in the
ﬁeld of HTA and included questions identiﬁed through informal
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the following: How do HTA practitioners currently approach reviewing for
model parameters? How do we know when we have adequate information and
does this vary for different types of parameters? Does the timing at which reviewing activity takes place vary
and should this commence at the beginning of the project? What is ideal practice and what changes could be made?
 What are the areas requiring further research?
In June 2010, a seminar was held at the School of Health and
Related Research and used as a member-checking device. All the
18 researchers among others were invited to the seminar where
further discussions were held on each of the key themes
identiﬁed in the focus group.
The key issues, identiﬁed through the initial pilot focus group
and seminar, were presented at a workshop held on February 7,
2011. This workshop included 13 participants from UK univer-
sities considered to be experts in the ﬁeld of HTA including seven
modelers, one health economist, one statistician, two informa-
tion specialists, and two reviewers. Purposive sampling was used
to identify participants. The workshop consisted of three focus
group sessions. Topic guides for the workshop focus groups
covered the following topics and questions that were generated
from ﬁndings of the pilot focus group and the subsequent
seminar: Model development (How does your “ﬁnal” model structure
arise? How do you know which parameters are relevant? How
iterative is the process?) Time constraints (What kind of compromises are acceptable
to make?) Sufﬁcient evidence (What is your interpretation of sufﬁcient
evidence?) Communication and teamwork (What deﬁnes good commu-
nication and teamwork in this context?) Problem structuring (How do you decide what should be
included in a model and what should be excluded?) Identiﬁcation of evidence (Do we need to provide guidance on
how to access nonstandard information? How do we handle
issues related to comprehensiveness and sensitivity? What
advice can we offer with respect to rapid searching?) Reviewing methods (How do we appraise for both quality and
relevance? How does the process of inclusion/exclusion differ
in the context of modeling? With rapid review methods what
compromises are we willing to make?) Recommendations for reporting (How do we report decision
making and judgments? What needs to be reported to allow
judgment of the credibility of the model?)
The discussions were open, and participants were invited to
discuss other points they felt were relevant but had not been
included in the guide.
Ethical approval for all focus groups was obtained from the
University of Shefﬁeld. The focus groups were facilitator-led (E.K.)
and were all recorded by using digital media, with the recordings
transcribed verbatim. Standard qualitative research methods
were used to conduct the focus groups [14]. Qualitative Frame-
work Analysis [15], which involves using a thematic framework to
classify and organize data according to key themes, subdivided
into related subtopics, was used to analyze the transcribed data.
An initial data familiarization process of the transcribed data was
undertaken. The data were coded, and a conceptual framework
was developed with a list of themes and related subthemes.
Coding and identiﬁcation of themes and subthemes was checkedby a second researcher. Some of the themes were preidentiﬁed,
and some were emergent.
The data obtained through the information gathering activ-
ities described above informed the development of guidance on
the reviewing of evidence to populate model parameters. A report
of the draft recommendations was shared with all workshop
participants for comment and revised accordingly.Results
Key themes related to the reviewing of model parameters
identiﬁed from the focus groups were 1) selection and prioritiza-
tion of data to inform parameter estimates, 2) reviewing meth-
ods, 3) minimizing bias, 4) hierarchies of evidence, 5) study
selection, 6) assessment of evidence, and 7) evidence synthesis
and analysis. These themes informed the statements presented
below. More detail of the focus group ﬁndings is available from
Kaltenthaler et al. [16,17], while more detail on the resulting
recommendations can be found in the TSD [12].
Theme 1: Selection and Prioritization of Data to Inform
Parameter Estimates
Every model parameter will need to be estimated; therefore, the
choices made regarding the values selected need to be explained
and justiﬁed. The choice of estimate will often be made according
to some trade-off or weighing up of the available options, rather
than according to rigid, predeﬁned criteria. This may be because
an estimate is required and there will usually be at best a range of
options, all of which may fall short of what would be considered
ideal to differing degrees. The nature of the trade-off between
selecting alternative parameter estimates will often include
considerations relating to quality versus relevance for each
option. Procedures associated with undertaking systematic
reviews can be used to make the process of choosing evidence
more systematic and transparent. Given the differences between
models and systematic reviews, however, the purposes for which
these procedures are undertaken and the sequence in which they
are undertaken may differ. In addition, time and resource con-
straints will have an impact on how they are undertaken. These
processes need to be justiﬁable and replicable. It is important to
prioritize parameters and focus reviewing resources on those
most likely to have an impact on model outputs, bearing in mind
that the importance of parameters is subject to change during the
course of the modeling process. Although some parameters will
be identiﬁed as important to the model early on in the process,
that is, they have an impact on the model outputs, the impor-
tance of some other parameters will be identiﬁed only later in the
process. A parameter may be considered important if the model
results are heavily inﬂuenced by it or it is identiﬁed as such by a
clinician or decision maker.
When model parameters are deemed to be important later in
the development process, time constraints necessitate the use of
rapid searching and review methods. Some caution is advised
with respect to using simple sensitivity analysis to prioritize
certain model parameters for detailed review, especially before
the model is ﬁnalized. If the model structure changes temporally
throughout its development process, or if other evidence is
identiﬁed to inform other model parameters, the original con-
clusions regarding the importance of a given model parameter
may no longer hold.
Theme 2: Reviewing Methods
Owing to time and resource constraints, it may be necessary to
use rapid review methods to identify and select evidence to
inform certain model parameters. Rapid review methods differ
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time frame and may have limited searching, appraisal, and
synthesis [18–20]. Timescales for reviewing may be shortened
by carefully focusing on the research question, conducting a
review of reviews, and extracting only key variables, among other
strategies [21]. The term rapid review, however, does not have one
single deﬁnition and neither the Cochrane Handbook [22] nor the
UK Centre for Reviews guidance [23] provides guidelines on
conducting them [24]. Other potentially relevant rapid review
methods in this context include reduced formal quality assess-
ment and reduced levels of synthesis.
Rapid review methods are not ideal because they risk missing
relevant information. It is therefore essential that methods be
reported in a transparent manner and that the limitations and
potential biases of the chosen approaches be addressed. Some
rapid methods used for reviewing clinical effectiveness evidence
may also be applicable for reviewing evidence to inform model
parameters, including the use of restricted review questions and
restrictions on included study designs. There may however be
issues with identifying suitable review methods for some model
parameters. For example, for reviews of health state utility values,
relevance needs to be assessed alongside the quality of studies [25].
Theme 3: Minimizing Bias
A variety of potential biases may be introduced through the
process of rapidly reviewing evidence to inform model parameter
estimates. These may include biases introduced through the use of
less thorough searching, potentially resulting in publication bias or
limiting appraisal or quality assessment, which may result in more
emphasis placed on poorer quality research or lack of attention to
synthesis, resulting in overlooking inconsistencies or contradic-
tions in the evidence [21]. Bias may also be introduced through the
purposive selection of evidence to create more or less favorable
results. One option to reduce such bias is to ensure and to
demonstrate that more than one member of the team is involved
with making decisions where choices about values need to be
made. This is partly because there may be more than one plausible
option, and a joint decision may provide a more robust and
systematic approach to considering the advantages and disadvan-
tages of each. Those involved in this decision-making process may
include clinical advisors, information specialists, systematic
reviewers, and other modelers on the team. In such circumstances,
the process of documenting the review methods used and high-
lighting their limitations should be considered important [21].
Theme 4: Hierarchy of Evidence
Types of evidence used to populate models will vary consider-
ably. Hierarchies of evidence sources as suggested by Coyle et al.
[2] may be of use as a means of judging the quality of individual
parameter estimates and aid the study selection process. While
hierarchies of evidence may be useful, there are other issues to
consider, including the quality of the individual studies. The
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) [26] system potentially provides a framework
for rating the quality of evidence from all potential sources of all
data components that may be used to populate model parame-
ters. It allows ﬂexibility in the quality assessment process to
include additional considerations alongside internal validity,
including (crucially for most data components used to populate
model parameters) applicability to the speciﬁc decision problem
at hand, which is part of the “indirectness” criterion in GRADE.
Thus, the extent to which the available evidence reﬂects levels
and combinations of resource use appropriate to the decision
under consideration is a key component of the quality
assessment.Theme 5: Study Selection
The deﬁnition of what is required may be based on an initial
understanding of what constitutes “relevant” evidence. The
objective is to identify a set of possible options from which
choices will be made. One option is to initially apply strict
selection. If no relevant studies are identiﬁed, the selection
criteria may then be broadened. It is important to explain the
process used and why it was chosen to justify the choices and to
maintain transparency. For many parameters there may be very
few sources and potential studies to use or alternatively many
good quality studies to choose from. If several potentially rele-
vant studies are identiﬁed, slightly stricter selection criteria may
be applied. In instances whereby a large number of sources are
identiﬁed, study selection using standard systematic review
processes of screening for titles, abstracts, and full texts may be
most appropriate. It is important to be as transparent as possible
about the judgments being made when selecting studies, for
example, stating which studies were deemed to be most relevant
to the setting under consideration.
Evidence used to inform model parameters will need to be
assessed on the basis of relevance to the context of the decision
problem, as well as quality. By assessing relevance ﬁrst, a large
number of studies may be eliminated. Ideally, criteria for rele-
vance should be established a priori. However, it is important to
recognize that it is not possible to have prespeciﬁed criteria for
every parameter as information needs may change (e.g., if the
model structure evolves) and information that was not expected
may be identiﬁed iteratively. Relevance criteria may therefore
change throughout the project; hence, ﬂexibility is essential.
What remains important is that the criteria or factors that inform
the choice of evidence remain clear. Anticipated evidence
requirements, as perceived during the earlier stages of model
development, may be identiﬁed by adopting an explicit stage of
conceptual model development before embarking on the math-
ematical model [27]. When the ﬁnal model is developed, it is
important to be clear how this deviated from the initial plan and
why to justify abstractions and simpliﬁcations driven by the
available evidence.
There is a tension between identifying all relevant evidence
and producing a model that is useful for informing decision
making. The deﬁnition of “relevance” is a subjective judgment,
and this may change over the course of developing a model. This
may be best avoided by determining evidence requirements early
on in the process by following a formal conceptual modeling
approach enabling dialogue between clinicians, decision makers,
and other stakeholders as to whether there is an agreed deﬁ-
nition of relevance. The use of a priori criteria for evidence review
and appraisal is also helpful.
Theme 6: Assessment of Evidence
After appraising studies for relevance, they can then be assessed
for quality, preferably by using standardized quality assessment
tools. In this context, quality assessment may be difﬁcult due to
the absence of standardized methods for all types of information
used to populate the model. Also, some studies may be poorly
reported. It may be possible to establish quality assessment
criteria a priori. An example of this is data collected for utility
studies, which may include study recruitment procedures, inclu-
sion and exclusion criteria, descriptions of the background
characteristics of the sample population from whom values are
obtained, response rates, and follow-up data [25]. Other issues to
consider include the type of reporting (self or proxy), follow-up
rates, number of patients, location, and methods of elicitation
among other issues. Establishing very broad a priori criteria may
be necessary, initially making quality assessment closely lined
with selection of evidence. Criteria may change according to the
Table 1 – Checklist of points to consider when
reviewing for model parameters.
Evidence requirements
 Identiﬁcation of parameters requiring evidence to inform them
(this may be supported by formal conceptual model development)
 Prioritization of evidence requirements by deciding on most
important parameters and revisiting this throughout the project
 Consideration of time available
Availability and selection of information
 Selection of appropriate search strategy
 Identiﬁcation of appropriate sources of evidence
 Consideration of the use of hierarchies of evidence
 Consideration of both quality and relevance when selecting
information
Rapid reviewing options
 Restricting review questions
 Establishing level of quality assessment needed
 Reducing level of data extraction
 Data extraction of key outcomes only
Reporting
 Transparent reporting of methods used
 Transparent reporting of choices about which evidence sources
have been used and those sources that have not
 Description of limitations of chosen methods
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“there were ﬁve options and we chose option 1 because of the
reasons a, b and c.” This also captures the necessary trade-off
between relevance and quality. It is important to be clear about
the factors or criteria that drive the choice and to examine the
implications of that choice. This level of transparency will allow
judgments to be made as to whether or not a reasonable choice
has been made. Because it can be very time consuming to judge
the quality of all potentially relevant studies, adjusting them
according to relevance and rigor may not be practical. Some types
of data are of potentially very poor quality, and it can be very
difﬁcult to identify appropriate sources of information, for exam-
ple, for cost data. These are not limitations of the cost-
effectiveness model but rather of the evidence base and as such
these evidence gaps should be exposed and clearly reported.
Data to be extracted from studies may include study date,
information on disease area and patients (age, sex, comorbid-
ities), study methods, outcomes, and other important descriptive
details. This can be set out a priori and presented in a way to
make it easy for the reader to compare and contrast the
characteristics of the available studies from which a selection
has been made, for example, using tables and/or graphs. This
level of detail is not appropriate for all parameter estimates but
should be reserved for those decisions whereby none of the
available studies is clearly superior or whereby evidence available
to inform a particular parameter or set of parameters is notably
weak. When extracting data from studies, it is important to
provide information for all the potentially relevant studies. By
providing a summary of all potentially relevant studies, the
reader is able to assess the study differences and heterogeneity
more accurately and to examine the spread of evidence. Infor-
mation from the studies that are not selected may be used to
inform the sensitivity analysis. Inconsistencies between different
estimates should be represented. Although the results presented
may be wide when using the available studies, it is important to
show how the range of values between disease stages or different
baseline event rates, for example, are driving the model results. It
is recognized that these suggestions may be quite time consum-
ing and there may be time and reporting constraints within an
HTA report. However, the overriding objective should be to
present the information and its implications on model results
as clearly as possible.
Theme 7: Evidence Synthesis
For many types of model parameters, the issue of synthesis may
not be considered relevant because of study heterogeneity. Often
only one or two values are appropriate for use in populating a
model parameter. Where there are more than one or two
potentially relevant studies, the issue of synthesis becomes
important. Guidance is available regarding evidence synthesis
techniques for model parameters [28–35]. A decision needs to be
made as to whether complex synthesis methods will provide a
meaningful value for a parameter. In some instances, however, it
may be simpler and more defensible to select the value from the
most appropriate and relevant study as opposed to using a
weighting system for pooling estimates. In some cases, it may
be reasonable to inﬂate the uncertainty associated with that
parameter estimate to reﬂect the range of other estimates that
have not been used. This should be judged on a case-by-case
basis. In instances whereby a quantitative synthesis is not
undertaken, however, this should be justiﬁed explicitly. The
choice of available evidence should be made clear and the
implication of choosing one source from a number of available
options explored through sensitivity analyses. While transpar-
ency and clear reporting are essential in exposing these types of
subjective model development decisions, it is essential that thisincludes consideration of the evidence that has been used to
inform the model parameters as well as the evidence that has not
been used.
The issues identiﬁed in this research have been incorporated
into a checklist, shown in Table 1. The purpose of the checklist is
to guide researchers through considerations regarding evidence
requirements, availability and selection of evidence, rapid review
options, and reporting throughout the model development
process.Discussion
This article has presented seven key themes exploring issues
around the reviewing of evidence to inform model parameters
informed by a series of information gathering activities with
experts in HTA in the United Kingdom. This research has focused
on issues of importance in NICE technology appraisals, which
involve mainly pharmaceutical interventions although the issues
raised are also relevant for HTAs of nonpharmaceutical inter-
ventions as well as other HTAs. The processes of selecting and
prioritizing data to inform parameter estimates were considered
to be important. There was agreement that reviewing effort
should be prioritized around the model parameters considered
to be important and reviewing methods chosen commensurate
with the parameter’s importance. Caution was advised however
as the importance of certain model parameters may change as
other parts of the model are developed and reﬁned. Also men-
tioned was the applicability of rapid reviewing methods. As
suggested by Watt et al. [19] and Ganann et al. [20], rather than
developing a formalized methodology to conduct rapid reviews,
which may be inappropriate and oversimpliﬁed, emphasis should
be placed on the transparent reporting of methods. The inclusion
of more than one team member in the process of choosing
appropriate parameter estimates was considered an option to
help to minimize bias.
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considered to be a potentially useful tool for guiding the choice of
evidence to inform parameter estimates although concerns were
raised because hierarchies do not take into account the quality of
the evidence. GRADE [26] may be useful in this context in that it
allows ﬂexibility in the quality assessment process to include
additional considerations alongside internal validity. Thus, the
extent to which the available evidence reﬂects levels and combi-
nations of resource use appropriate to the decision under con-
sideration is a key component of the quality assessment. Sources
of data that could be incorporated by using GRADE include
national disease registers, claims, prescriptions or hospital activ-
ity databases, or standard reference sources such as drug for-
mularies or collected volumes of unit costs [36,37].
Both quality and relevance were considered to be important
when undertaking study selection. Quality assessment of the
evidence was thought to present some challenges due to the
absence of quality assessment tools for many types of evidence
used to populate cost-effectiveness models. With regard to choices
made related to evidence synthesis and analysis, these need to be
made clear and explicitly justiﬁed. Study selection processes need
to be clearly reported, and there should be transparency around
what judgments have been made regarding study selection.
There are some limitations to this study. First, focus groups
were used as the main method of data collection in this study.
Other qualitative methods such as in-depth interviews [38] or
consensus techniques [39] could have been used in this research
and may have yielded different results. The initial pilot focus
group that informed later elements of the study included
researchers only from one institution. Using a wider group of
researchers for the pilot focus group may have ensured that the
results were more representative of practice in this ﬁeld. The
later workshop did however include HTA experts from several
institutions in the United Kingdom. The study was focused on the
needs of NICE health technology appraisals, and more research is
needed to determine the reviewing needs for model parameters
within HTAs for other decision makers.
The issues raised in this research are important in the ﬁeld of
HTA. The principles of evidence-based medicine lie at the heart
of HTA; hence, questions regarding the identiﬁcation and selec-
tion of evidence inevitably inﬂuence the structure, conclusions,
and consequences of any HTA model. Whether the model results
are credible is always a matter of subjective judgment and is
dependent on the interpretation of the reader/decision maker. It
is for precisely these reasons that we would advocate the need to
make clear the subjective nature of the approach used and the
other alternatives available that have not been followed and to
examine, where possible, the likely impact of these choices on
the model results. There is a need for agreed standardized
practice in this area while still maintaining ﬂexibility and adapt-
ability to suit the needs of individual HTAs. As Cooper et al. [3]
state, “it is imperative that evidence for all model parameters is
identiﬁed systematically, quality assessed and where applicable
pooled using explicit criteria and reproducible methods.” The
ﬁndings from this research support this statement. A systematic,
transparent, and reproducible process is essential for the devel-
opment of cost-effectiveness models to support HTAs. Further
research is needed in this area and includes the need for the
development of appropriate rapid reviewing methods, quality
assessment tools for nonstandard sources of evidence, investi-
gation into the use of hierarchies of evidence and GRADE,
development of the methods used for the selection of evidence,
and development of reporting standards.
This article goes some way in ensuring that those involved in
modeling within HTAs are able to engage with the issues
associated with the selection and review of evidence to inform
model parameters. Potential solutions have been offered toensure that this is done in a systematic fashion and to improve
the transparency of reporting of the modeling process.
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